Dexamethasone induces the expression of metalloproteinase inhibitor TIMP-1 in the murine cerebral vascular endothelial cell line cEND

被引:79
作者
Foerster, Carola
Kahles, Timo
Kietz, Silke
Drenckhahn, Detlev
机构
[1] Univ Wurzburg, Inst Anat & Cell Biol, D-97070 Wurzburg, Germany
[2] Goethe Univ Frankfurt, Dept Neurol, Univ Hosp Frankfurt, D-60528 Frankfurt, Germany
[3] Univ Gottingen, Zentrum Kinderheilkunde & Jugendmed, D-37075 Gottingen, Germany
来源
JOURNAL OF PHYSIOLOGY-LONDON | 2007年 / 580卷 / 03期
关键词
D O I
10.1113/jphysiol.2007.129007
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
In many neuroinflammatory conditions, including multiple sclerosis (MS), encephalitis, meningitis, brain tumours and cerebral ischaemia, the matrix metalloproteinases (MMPs) play an important role in disrupting the blood-brain barrier (BBB). Normally under tight regulation, increased MMP-9 cerebrospinal fluid levels and excessive proteolytic activity is detected in the blood and cerebrospinal fluid in patients with acute MS. MMP-9 is a member of the type IV collagenases, which attack components of the endothelial basal lamina, including type IV collagen. The disruption of the BBB and clinical symptoms can be reduced with different inhibitors to MMPs including activators of tissue inhibitor of metalloproteinases-1 (TIMP-1), the cognate tissue inhibitor of MMP-9. Since intravenous glucocorticoid (GC) treatment reduces the levels of MMP-9 markedly in patients, we hypothesized that GC effects might be mediated by transcriptional activation of the TIMP-1 gene in addition to reported repressive effects on MMP-9 transcription. Our results provide direct evidence that GCs increase TIMP-1 in the brain endothelial cell line cEND, prevent alterations in microvascular integrin alpha 1 subunit expression and help maintain endothelial barrier function in response to pro-inflammatory stimuli (TNF alpha administration). GC-induced up-regulation of TIMP-1 expression by the CNS vascular endothelium may thus play a role in preservation of the endothelial basal lamina and maintain integrin alpha 1 and tight junction protein expression important for vessel wall integrity.
引用
收藏
页码:937 / 949
页数:13
相关论文
共 57 条
[1]   Glucocorticoid-regulated transcription factors [J].
Adcock, IM .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2001, 14 (03) :211-219
[2]   The antiglucocorticoid action of mifepristone [J].
Agarwal, MK .
PHARMACOLOGY & THERAPEUTICS, 1996, 70 (03) :183-213
[3]   ROLE OF ACIDIC AND PHOSPHORYLATED RESIDUES IN GENE ACTIVATION BY THE GLUCOCORTICOID RECEPTOR [J].
ALMLOF, T ;
WRIGHT, APH ;
GUSTAFSSON, JA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (29) :17535-17540
[4]   DIFFERENCES IN LAMININ FRAGMENT INTERACTIONS OF NORMAL AND TRANSFORMED ENDOTHELIAL-CELLS [J].
AUMAILLEY, M ;
TIMPL, R ;
RISAU, W .
EXPERIMENTAL CELL RESEARCH, 1991, 196 (02) :177-183
[5]   Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment [J].
Avolio, C ;
Filippi, M ;
Tortorella, C ;
Rocca, MA ;
Ruggieri, M ;
Agosta, F ;
Tomassini, V ;
Pozzilli, C ;
Stecchi, S ;
Giaquinto, P ;
Livrea, P ;
Trojano, M .
MULTIPLE SCLEROSIS, 2005, 11 (04) :441-446
[6]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[7]   Tissue inhibitors of metalloproteinases: evolution, structure and function [J].
Brew, K ;
Dinakarpandian, D ;
Nagase, H .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 2000, 1477 (1-2) :267-283
[8]   THE EFFECT OF HIGH-DOSE STEROIDS ON MRI GADOLINIUM ENHANCEMENT IN ACUTE DEMYELINATING LESIONS [J].
BURNHAM, JA ;
WRIGHT, RR ;
DREISBACH, J ;
MURRAY, RS .
NEUROLOGY, 1991, 41 (09) :1349-1354
[9]   The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis [J].
Chang, C ;
Werb, Z .
TRENDS IN CELL BIOLOGY, 2001, 11 (11) :S37-S43
[10]   Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter [J].
Chen, YP ;
Ferguson, SS ;
Negishi, M ;
Goldstein, JA .
MOLECULAR PHARMACOLOGY, 2003, 64 (02) :316-324